# Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)

> **NCT05885009** · — · RECRUITING · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 240 (estimated)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **GENETIC:** Liquid Biopsy
- **GENETIC:** Archival Tumor DNA sequencing

## Key facts

- **NCT ID:** NCT05885009
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-28
- **Primary completion:** 2026-03-28
- **Final completion:** 2028-03-28
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-08-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05885009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05885009, "Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05885009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*